A phase I/II clinical trial of neoadjuvant docetaxel/oxaliplatin/S‑1 (DOS) combination therapy for gastroesophageal junction adenocarcinoma
Journal of Gastroenterology · 2026
DOI: 10.1007/s00535-026-02366-9 ↗Kurz gefasst
Klinische Studie (Phase II) in der Zeitschrift Journal of Gastroenterology, 2026. Verfasst von Koshi Kumagai und 18 weiteren Autor:innen. Beteiligte Einrichtung: Department of Upper Gastrointestinal Surgery, Kitasato University School of Medicine, 1-15-1 Kitasato, Minami-ku, Sagamihara, Kanagawa, 252-0374, Jap…. Hauptthemen laut MEDLINE: Adenocarcinoma, Esophagogastric Junction, Antineoplastic Combined Chemotherapy Protocols, Stomach Neoplasms. Die Arbeit nennt 33 Literaturangaben.
Abstract (Originalsprache)
BACKGROUND: Gastroesophageal junction (GEJ) adenocarcinoma is aggressive with poor prognosis. Perioperative chemotherapy has become standard, but the optimal regimen remains uncertain. DOS has shown activity in gastric cancer but has not been prospectively assessed in GEJ adenocarcinoma. This study represents the first prospective trial of DOS as neoadjuvant chemotherapy in patients with resectable GEJ adenocarcinoma. METHODS: This single-arm, single-center phase I/II trial (UMIN000022210) enrolled patients with cT3-4aN0-3M0 GEJ adenocarcinoma. The phase I part established the recommended docetaxel dose (60 mg/m2); phase II evaluated efficacy and safety. The primary endpoint was R0 resection rate; and secondary endpoints included pathological response, adverse events, and 3-year survival. RESULTS: Forty-three patients were enrolled; 37 received DOS at the recommended dose. Of these, 83.8% completed all planned cycles. Grade ≥ 3 neutropenia occurred in 81.1%, and febrile neutropenia in 18.9%. The R0 resection rate was 94.6% (35/37; 95% CI, 81.8-99.3). Major postoperative complications occurred in 11.4%, with no operative mortality. Major pathological response was achieved in 40.5% of patients, including a pathological complete response rate of 5.4%. At 3 years, overall survival and relapse-free survival were 84.9% and 64.5%, respectively. Patients downstaged to ypStage 0 or IA had significantly better relapse-free survival than others. CONCLUSIONS: Neoadjuvant DOS chemotherapy showed high R0 resection rates, acceptable toxicity, and favorable survival in resectable GEJ adenocarcinoma, supporting its potential as a treatment option. These findings provide important evidence from East Asia, where S-1-based regimens remain widely used, and complement Western data on perioperative FLOT therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Upper Gastrointestinal Surgery, Kitasato University School of Medicine, 1-15-1 Kitasato, Minami-ku, Sagamihara, Kanagawa, 252-0374, Japan. kumagai.koshi@kitasato-u.ac.jp.
- Department of Surgery, Shonan Kamakura General Hospital, Kamakura, Japan.
- Department of Medical Oncology, Kyoto University Graduate School of Medicine, Kyoto, Japan.
- Department of Gastroenterology, Kitasato University School of Medicine, Sagamihara, Japan.
- Department of Surgery, International University of Health and Welfare, Mita Hospital, Tokyo, Japan.
- Department of Upper Gastrointestinal Surgery, Kitasato University School of Medicine, 1-15-1 Kitasato, Minami-ku, Sagamihara, Kanagawa, 252-0374, Japan.
ORCID-Profile: Koshi Kumagai
Zitieren
APA
Kumagai, K., Hosoda, K., Katada, C., Ishido, K., Watanabe, A., Wada, T., Niihara, M., Higuchi, T., Sakuraya, M., Washio, M., Chuman, M., Harada, H., Fujita, S., Okuno, K., Yamashita, K., Kumamoto, Y., Naitoh, T., Kusano, C., & Hiki, N. (2026). A phase I/II clinical trial of neoadjuvant docetaxel/oxaliplatin/S‑1 (DOS) combination therapy for gastroesophageal junction adenocarcinoma. Journal of Gastroenterology. https://doi.org/10.1007/s00535-026-02366-9
Vancouver
Kumagai K, Hosoda K, Katada C, Ishido K, Watanabe A, Wada T, et al. A phase I/II clinical trial of neoadjuvant docetaxel/oxaliplatin/S‑1 (DOS) combination therapy for gastroesophageal junction adenocarcinoma. Journal of Gastroenterology. 2026. doi:10.1007/s00535-026-02366-9
BibTeX
@article{Kumagai2026,
author = {Kumagai, Koshi and Hosoda, Kei and Katada, Chikatoshi and Ishido, Kenji and Watanabe, Akinori and Wada, Takuya and Niihara, Masahiro and Higuchi, Tadashi and Sakuraya, Mikiko and Washio, Marie and Chuman, Motohiro and Harada, Hiroki and Fujita, Shohei and Okuno, Kota and Yamashita, Keishi and Kumamoto, Yusuke and Naitoh, Takeshi and Kusano, Chika and Hiki, Naoki},
title = {A phase I/II clinical trial of neoadjuvant docetaxel/oxaliplatin/S‑1 (DOS) combination therapy for gastroesophageal junction adenocarcinoma},
journal = {Journal of Gastroenterology},
year = {2026},
doi = {10.1007/s00535-026-02366-9}
}
EUVIMED